Welcome to our dedicated page for Relmada Therapeutics SEC filings (Ticker: RLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Relmada Therapeutics, Inc. (RLMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Relmada identifies itself in these documents as a Nevada corporation with common stock listed on the Nasdaq Capital Market under the symbol RLMD and principal offices in Coral Gables, Florida.
Through forms such as Form 8‑K, Relmada reports material events related to its business. Recent 8‑K filings describe topics including: written FDA feedback on planned Phase 3 registrational trials for NDV-01 in non-muscle invasive bladder cancer; preliminary nine‑month safety and efficacy data from the NDV-01 Phase 2 study; quarterly financial updates; an underwritten offering of common stock and pre-funded warrants; Nasdaq minimum bid price compliance matters; and amendments to executive employment agreements. These filings often incorporate press releases as exhibits and summarize key financial or clinical information referenced in company news.
Investors interested in capital structure and financing can review 8‑K disclosures regarding the terms of underwritten offerings, pre-funded warrants, and related legal opinions. Those focused on governance and compensation can examine filings detailing amended and restated employment agreements for executive officers, including changes to salary and severance provisions.
While this page emphasizes current and historical 8‑K reports, Relmada also files other periodic and registration statements, such as Forms 10‑Q, 10‑K, and S‑3, that contain more extensive financial statements, risk factor discussions, and descriptions of its NDV-01 and sepranolone development programs. Stock Titan enhances access to these documents by pairing them with AI-powered tools that help explain filing contents, highlight key sections, and make it easier to locate information on topics such as clinical trial plans, cash resources, listing status, and executive arrangements.
Relmada Therapeutics, Inc. received an updated ownership report showing a near-10% stake held by Squadron-affiliated funds and principals. Squadron Master Fund LP, together with Squadron Capital Management, LLC, William Blank, and Matthew Sesterhenn, report beneficial ownership of 7,395,510 shares of Common Stock.
This position consists of 6,700,000 common shares plus 695,510 shares issuable upon exercise of warrants held by Squadron Capital Management, LLC. Based on 73,333,622 shares outstanding as of November 10, 2025, plus these warrant shares, the group’s holdings represent approximately 9.99% of Relmada’s common stock.
The Squadron entities and individuals report shared voting and dispositive power over all 7,395,510 shares and no sole power. The investment adviser and its partners expressly disclaim beneficial ownership and state that the securities are held in the ordinary course of business, not for the purpose of changing or influencing control of Relmada.
Relmada Therapeutics, Inc. disclosed that investment manager Spruce Street Capital LP, together with Alex R. Rosen and Simon Basseyn, reported beneficial ownership of 4,086,181 shares of common stock, representing 5.57% of the company. This percentage is based on 73,333,622 shares outstanding as of November 10, 2025. The investors certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Relmada.
Relmada Therapeutics, Inc. is the subject of a Schedule 13G showing that Adage Capital Management, L.P. and related individuals beneficially own 4,270,000 shares5.82% of the class. This percentage is based on 73,333,622 shares outstanding as of November 10, 2025.
The reporting persons have shared voting and dispositive power over all reported shares and no sole power. They state the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Relmada Therapeutics.
Janus Henderson Group plc filed a Schedule 13G reporting beneficial ownership of 7,439,415 shares of Relmada Therapeutics, Inc. common stock, representing 10.1% of the class. The shares are held across various managed portfolios of Janus Henderson’s asset management subsidiaries, which exercise investment and voting discretion.
Janus Henderson reports shared voting and shared dispositive power over all reported shares, with no sole voting or dispositive power. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Relmada Therapeutics.
Relmada Therapeutics, Inc. has updated its at-the-market stock sales program to offer up to $100,000,000 of common stock through Jefferies LLC as sales agent under an existing Open Market Sale Agreement.
The company states it has not previously sold any shares under this program and is amending the prior prospectus materials to reflect the higher aggregate amount. Relmada’s common stock trades on the Nasdaq Global Select Market under the symbol RLMD, and the last reported sale price was $3.91 per share on January 29, 2026. The company also notes it is no longer subject to the Form S-3 General Instruction I.B.6 limitations because the aggregate market value of its non-affiliate holdings was at least $75.0 million as of January 28, 2026.
Relmada Therapeutics CEO and director Sergio Traversa reported buying 27,500 shares of the company’s common stock in multiple open market transactions at a weighted average price of $4.12 per share, with individual purchase prices ranging from $4.10 to $4.12.
Following these purchases, he beneficially owns 1,300,000 common shares directly. Traversa was also granted 1,198,000 stock appreciation rights with a conversion price of $4.06, each linked to one share of common stock. These rights vest in 16 equal quarterly installments beginning on March 12, 2026 and expire on December 12, 2035, with 1,198,000 derivative securities shown as beneficially owned after the transaction.
Relmada Therapeutics, Inc.'s chief financial officer reported buying 11,665 shares of common stock on December 15, 2025 at $4.12 per share, bringing his directly held stake to 800,000 shares. In a separate transaction on December 12, 2025, he was granted 828,000 stock appreciation rights with a $4.06 exercise price, each linked to one share of common stock and expiring on December 12, 2035. These rights begin vesting on March 12, 2026 in 16 equal quarterly installments, providing additional long-term equity-based compensation tied to the company’s stock.
Relmada Therapeutics, Inc. reported that one of its officers with the title "CA and CO" received 828,000 stock appreciation rights12/12/2025$4.0603/12/202612/12/203516 equal quarterly installments828,000 derivative securities
Relmada Therapeutics director Fabiana Fedeli reported receiving a grant of 164,000 stock appreciation rights on December 12, 2025. These derivative securities relate to Relmada Therapeutics common stock and carry an exercise price of $4.06 per right. The award was reported as an acquisition transaction and is held with direct ownership.
The stock appreciation rights are scheduled to vest in 16 equal quarterly installments, commencing on March 12, 2026, providing a staged vesting profile over time. The instruments become exercisable starting March 12, 2026 and have an expiration date of December 12, 2035, giving a long-dated window in which they may be exercised.
Relmada Therapeutics director John Glasspool reported a new equity award in the form of stock appreciation rights. On 12/12/2025, he was granted 164,000 stock appreciation rights with a conversion or exercise price of $4.06, each tied to one share of Relmada common stock.
The award is structured as a long-term incentive. It begins vesting on March 12, 2026, in 16 equal quarterly installments and expires on 12/12/2035. Following this grant, Glasspool beneficially owns 164,000 derivative securities directly, all linked to Relmada’s common stock.